AMGEN INC shareholders Q2 2024

AMGEN INC's ticker is AMGN and the CUSIP is 031162100. A total of 2,715 filers reported holding AMGEN INC in Q2 2024. The put-call ratio across all filers is 0.88 and the average weighting 0.4%.

AMGEN INC shareholders Q2 2024
NameSharesValueWeighting ↓
Round Hill Asset Management 48,060$15,016,3479.58%
Aaron Wealth Advisors LLC 205,447$64,191,9158.91%
Oak Asset Management, LLC 63,465$19,829,5037.26%
Biechele Royce Advisors 67,072$20,9577.08%
Tri Locum Partners LP 82,271$25,705,5746.50%
IAT REINSURANCE CO LTD. 92,500$28,901,6256.10%
Cutter Capital Management, LP 64,201$20,059,6026.06%
Wilkinson Global Asset Management LLC 293,369$91,663,1445.73%
Smead Capital Management, Inc. 1,133,307$354,101,7725.53%
Eliot Finkel Investment Counsel, LLC 26,162$8,174,3175.38%
Deep Track Capital, LP 575,000$179,658,7505.36%
JMAC ENTERPRISES LLC 96,550$30,166,9705.30%
HealthInvest Partners AB 27,589$8,620,1835.26%
MONTRUSCO BOLTON INVESTMENTS INC. 1,557,709$475,418,7264.99%
O'Keefe Stevens Advisory, Inc. 47,642$14,885,6294.98%
Redwood Grove Capital, LLC 50,387$15,743,4184.93%
EDMP, INC. 17,172$5,365,3914.86%
Osher Van de Voorde Investment Management 66,939$20,915,0914.82%
Nepsis Inc. 55,980$17,490,9514.72%
R.H. Dinel Investment Counsel, Inc. 23,050$7,201,9734.61%
About AMGEN INC

Amgen Inc. is a biotechnology company that specializes in the development of innovative medicines for the treatment of serious illnesses. The company has a strong track record of success, with a portfolio of products that includes some of the most widely used and effective drugs in the world.

One of Amgen's most important products is Enbrel, a drug used to treat rheumatoid arthritis and other autoimmune diseases. Enbrel has been a major success for the company, generating billions of dollars in revenue each year.

Amgen is also a leader in the development of cancer treatments, with a number of promising drugs in its pipeline. The company's cancer drugs are designed to target specific types of cancer cells, which can help to minimize side effects and improve patient outcomes.

In addition to its focus on drug development, Amgen is also committed to sustainability and social responsibility. The company has implemented a number of initiatives to reduce its environmental impact, and it has also established programs to support education and healthcare in underserved communities.

Overall, Amgen is a company with a strong track record of success and a commitment to innovation and social responsibility. With a portfolio of products that includes some of the most effective drugs in the world, Amgen is well positioned for continued growth and success in the years ahead.

It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.

External links

This page lists AMGEN INC's shareholders in Q2 2024. To view AMGEN INC's shareholder history, click here.